Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Tesaro Inc.

Latest From Tesaro Inc.

Myriad Foresees Important Role For Genetic Testing In Pancreatic Cancer, Breast Cancer And Beyond

The results of the POLO trial, showing a benefit of Myriad’s BRACAnalysis CDx companion diagnostic for AstraZeneca’s Lynparza (olaparib) to treat pancreatic cancer offer more support for the new guidelines from the National Comprehensive Cancer Network recommending genetic testing for all pancreatic cancer patients. Myriad also stands to benefit from the growing support for genetic testing of breast cancer patients.

ASCO In Vitro Diagnostics

AZ/Merck & Co’s Lynparza POLO Study ‘Practice Changing’ For Pancreatic Cancer Subgroup

A near doubling of progression-free survival in the POLO study of AstraZeneca/Merck & Co’s Lynparza could usher in a new era of targeted therapy for metastatic pancreatic patients with germline BRCA mutations, and open up a third indication for the leading PARP inhibitor.

ASCO Cancer

GSK Revamps Sales Reps Incentives To Be Competitive In Cancer

Seven years after a major shift in how the company compensated its sales force, the UK major has done a U-turn and is adapting pay packages for some specialty care reps.

Business Strategies Commercial

What Late-Breakers To Look Out For At ASCO 2019

Delegates at this year’s ASCO meeting in Chicago will hear late-breaking clinical data for a number of studies from AstraZeneca, Novartis, Pfizer, Astellas, Merck & Co and Seattle Genetics which are set to shake up their respective markets. There will also be more clarity on where Lilly’s Lartruvo went so wrong.

ASCO Clinical Trials
See All

Company Information

  • Industry
  • Biotechnology
  • Pharmaceuticals
    • Specialty Pharmaceuticals
  • Therapeutic Areas
  • Cancer
  • Alias(es)
  • Ownership
  • Public
  • Headquarters
  • Worldwide
    • North America
      • USA
  • Parent & Subsidiaries
  • Tesaro Inc.
  • Senior Management
  • Lonnie Moulder, CEO
    Timothy Pearson, EVP, CFO
    Mary Lynne Hedley, PhD, Pres. & COO
    Grant C Bogle, SVP, Chief Commercial Officer
    William Aitchison, PhD, SVP, Technical ops
    Allene Diaz, SVP, Global Commercial Development
    Joseph Farmer, SVP, General Counsel & Corp Secretary
    Martin Huber, MD, SVP, CMO
    Jennifer Jackson, PhD, SVP, Global RA and QA
    Orlando Oliveira, SVP, International
  • Contact Info
  • Tesaro Inc.
    Phone: (339) 970-0900
    1000 Winter St.
    Ste. 3300
    Waltham, MA 02451